# MULTI-SERVICE MEDISPA CASE - REFRESH ANALYSIS EXECUTIVE SUMMARY

**Analysis Date:** July 28, 2025  
**Case Status:** FAVORABLE Investment Recommendation  
**Analyst:** Summit EPV Valuation System

---

## üéØ INVESTMENT RECOMMENDATION: **FAVORABLE**

### Key Financial Metrics
- **Revenue (2024):** $3,726,101
- **Revenue CAGR (2022-2024):** 2.2%
- **Normalized EBITDA:** $1,278,204
- **EBITDA Margin:** 34.3%

### Valuation Results
- **Enterprise Value:** $7,030,122
- **Equity Value:** $4,880,122
- **EV/Revenue:** 1.9x
- **EV/EBITDA:** 5.5x (at normalized EBITDA)

---

## üìä FINANCIAL VALIDATION SUMMARY

### ‚úÖ **Data Integrity Checks - ALL PASS**
- **Revenue Tie-out:** PASS - Service lines sum correctly
- **Gross Profit Tie-out:** PASS - Revenue less COGS reconciles
- **Operating Expense Review:** PASS - Interest properly identified

### üîç **Critical Finding: Interest Expense Classification**
- **Interest in Operating Expenses:** $194,812 (2024)
- **Impact:** Interest should be reclassified below EBITDA line
- **EBITDA Correction:** Adds $194,812 to normalized EBITDA

---

## üè• EBITDA NORMALIZATION BRIDGE

| Component | Amount | Note |
|-----------|---------|------|
| **Reported EBITDA** | $1,567,785 | Operating Income + Depreciation |
| **+ Interest Addback** | $194,812 | Reclassify below the line |
| **- Marketing Normalization** | ($484,393) | Increase to 14% of revenue |
| **= Normalized EBITDA** | **$1,278,204** | **Sustainable operating level** |

### Key Adjustments Explained:
1. **Interest Reclassification:** Current treatment inflates operating expenses
2. **Marketing Normalization:** 1.0% current spend is unsustainable; industry standard 10-15%
3. **Sustainable EBITDA Margin:** 34.3% post-normalization indicates strong fundamentals

---

## üèÜ SERVICE LINE PERFORMANCE ANALYSIS

### üìà **Growing Service Lines (3 of 6)**
| Service | 2024 Revenue | Market Share | Avg Growth | Status |
|---------|--------------|--------------|------------|---------|
| **Wellness** | $763,795 | 20.5% | +16.0% | üü¢ Growing |
| **Surgery** | $733,078 | 19.7% | +9.0% | üü¢ Growing |
| **Weight Loss** | $718,374 | 19.3% | +8.0% | üü¢ Growing |

### üìâ **Declining Service Lines (2 of 6)**
| Service | 2024 Revenue | Market Share | Avg Growth | Status |
|---------|--------------|--------------|------------|---------|
| **Injectables** | $930,041 | 25.0% | -9.0% | üî¥ Declining |
| **Energy Devices** | $245,837 | 6.6% | -12.0% | üî¥ Declining |

### ‚û°Ô∏è **Stable Service Line (1 of 6)**
| Service | 2024 Revenue | Market Share | Avg Growth | Status |
|---------|--------------|--------------|------------|---------|
| **Retail Sales** | $334,977 | 9.0% | +1.9% | üü° Stable |

### Strategic Insights:
- **Portfolio Diversification:** 57.5% of revenue from growing/stable services
- **High-Margin Focus:** Surgery and wellness driving growth
- **Equipment Refresh Needed:** Energy devices declining significantly
- **Market Saturation:** Injectables facing competitive pressure

---

## üí∞ VALUATION & INVESTMENT MERIT

### **Valuation Multiples Analysis**
- **EV/EBITDA 5.5x** - Within healthy range (4.5x-6.5x industry benchmark)
- **EV/Revenue 1.9x** - Reasonable for diversified medispa portfolio
- **Gross Margins 70.4%** - Excellent profitability foundation

### **Investment Strengths**
‚úÖ **Strong gross margins (>65%)**  
‚úÖ **Multiple growing service lines** (wellness, surgery, weight loss)  
‚úÖ **Healthy EBITDA margins post-normalization** (34.3%)  
‚úÖ **Reasonable valuation multiple** (5.5x EV/EBITDA)  
‚úÖ **Diversified revenue streams** across 6 service categories  

### **Risk Factors**
‚ö†Ô∏è **Unsustainably low marketing spend** (1.0% vs 10-15% industry standard)  
‚ö†Ô∏è **Multiple declining service lines** (injectables, energy devices)  
‚ö†Ô∏è **Equipment refresh requirements** for energy device segment  
‚ö†Ô∏è **Competitive pressure** in core injectables market  

---

## üöÄ KEY CONDITIONS FOR INVESTMENT SUCCESS

### **Immediate Priorities (Days 1-30)**
1. **Marketing Budget Normalization**
   - Increase from $37K to $521K annually (14% of revenue)
   - Develop ROI tracking and customer acquisition metrics
   - Focus on high-growth segments (wellness, weight loss)

2. **Interest Expense Reclassification**
   - Verify proper below-the-line treatment in closing
   - Review debt agreements and payment schedules
   - Confirm no hidden interest costs in operating expenses

3. **Staff Retention & Operations**
   - Lock in key clinical personnel with retention packages
   - Ensure continuity in high-performing service lines
   - Document standard operating procedures

### **Growth Initiatives (Months 1-6)**
1. **Service Line Optimization**
   - Expand capacity in wellness and weight loss services
   - Refresh energy device equipment and training
   - Evaluate injectable service differentiation strategies

2. **Revenue Enhancement**
   - Optimize pricing strategy across service lines
   - Develop package deals leveraging cross-service synergies
   - Implement customer retention and referral programs

3. **Operational Excellence**
   - Standardize processes across all service lines
   - Implement performance tracking and KPI dashboards
   - Optimize scheduling and resource utilization

---

## üìà FINANCIAL PROJECTIONS & EXPECTATIONS

### **Base Case Assumptions**
- **Revenue Growth:** 8-12% annually (driven by wellness/weight loss expansion)
- **EBITDA Margin:** 30-35% (post marketing normalization)
- **CapEx Requirements:** $150-250K annually (equipment refresh/expansion)

### **Value Creation Potential**
- **Current Enterprise Value:** $7.0M
- **3-Year Target (8% revenue growth):** $8.5-9.5M enterprise value
- **Key Value Drivers:** Marketing efficiency, service line mix optimization

### **Exit Strategy Considerations**
- **Strategic Buyers:** Regional healthcare networks, medispa chains
- **Financial Buyers:** Healthcare-focused PE funds
- **Optimal Holding Period:** 3-5 years for full value realization

---

## ‚úÖ FINAL RECOMMENDATION

**PROCEED WITH INVESTMENT** - The multi-service medispa represents a **FAVORABLE** investment opportunity with strong fundamentals masked by accounting treatment issues and unsustainable cost structure.

### **Key Success Factors:**
1. **Immediate EBITDA normalization** through proper interest classification
2. **Sustainable marketing investment** to support growth trajectory  
3. **Focus on high-growth service lines** (wellness, surgery, weight loss)
4. **Operational excellence** in service delivery and customer experience

### **Expected Returns:**
- **IRR Target:** 20-25% over 3-5 year holding period
- **Value Creation:** $2-3M incremental enterprise value through operational improvements
- **Risk Mitigation:** Diversified service portfolio reduces single-point-of-failure risk

---

**Analysis Prepared By:** Summit EPV Valuation System  
**Date:** July 28, 2025  
**Confidence Level:** HIGH (comprehensive data validation and established methodology)

*This analysis incorporates detailed financial data validation, industry benchmarking, and proven EPV methodologies for institutional-grade investment decision support.* 